ACER - オペクサ・セラピュ―ティクス （Acer Therapeutics Inc.） オペクサ・セラピュ―ティクスACERのチャート
ACERの企業情報
| symbol | ACER |
|---|---|
| 会社名 | Acer Therapeutics Inc （オペクサ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オペクサ・セラピューティクス(Opexa Therapeutics Inc)はバイオ医薬品企業。同社は多発性硬化症(MS)などの疾患に対する治療の可能性のある個別化細胞療法の開発に従事する。それらの治療法は同社のT細胞技術をベースとしている。同社の主な製品候補であるTovaxinはベーラー医科大学（Baylor College of Medicine）からライセンスを受けた、MS治療用の臨床開発中の個別化T細胞治療ワクチンである。TcelnaはT細胞の免疫療法であり、IIb期臨床開発中の二次進行型MS（SPMS）治療用に使用される。Tcelnaは患者の疾患プロファイルに特に合わせる個人向け治療法である。TERMS研究は臨床分離症候群リスクの高いあるいは再発寛解型多発性硬化症（RRMS）を患っている150位患者を対象とする多中心の無作為プラセボ比較二重盲検臨床試験である。 オペクサ・セラピュ―ティクスは米国のバイオ医薬品会社。多発性硬化症(MS)など重篤な疾病、及び視神経脊髄炎などの免疫性疾患の自己免疫療法の開発に従事。独自に開発したT細胞技術に基づき、二次進行型MSや再発寛解型MSなどの治療薬の臨床開発段階にある。また、血液から単球由来幹細胞を生成するための成体幹細胞技術を開発。本社はテキサス州。 Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. |
| 本社所在地 | One Gateway Center Suite 351 300 Washington St. Newton MA 02458 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 33298 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 6人 |
| url | www.acertx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acer |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.45878 |
| 終値（lastsale） | 28.37 |
| 時価総額（marketcap） | 285203269.56 |
| 時価総額 | 時価総額（百万ドル） 282.99160 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 274.64783 |
| 当期純利益 | 当期純利益（百万ドル） -16.51118 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Acer Therapeutics Inc revenues was not reported. Net loss increased 36% to $8.8M. Higher net loss reflects General and administrative increase from $1.5M to $4.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.01 to -$1.18. |
ACERのテクニカル分析
ACERのニュース
7 Micro-Cap Stocks to Buy for Risk-Taking Investors 2023/01/27 12:05:00 InvestorPlace
Now’s a great time to start considering which micro-cap stocks to buy. Generally, micro-caps are stocks with a market capitalization of less than $300 million. With a cap like that, the company doesn’t have a ton of resources – which means that it could be forced to go into debt in order to grow, or it may not have enough wiggle room to withstand extended losses or mismanagement. It’s not uncommon to see some of the most interesting micro-cap stocks to buy trading on over-the-counter indices rather than the New York Stock Exchange or the Nasdaq. If that’s the case with a company you’re considering, just keep in mind that OTC markets or pink sheets don’t have the same listing standards as the major indices. That means that as an investor you will likely have less information to go on as you make your decision to buy, sell or hold. I’m using my Portfolio Grader tool to help us with an evaluation of some high-risk micro-cap stocks to buy. These names all have an “A” or “B” grade in the Portfolio Grader based on their earnings history, performance, momentum and other factors.
After A -20.98% Drop In The Last Week, Does Acer Therapeutics Inc. (NASDAQ: ACER) Still Make Sense To Buy? 2023/01/21 12:00:00 Marketing Sentinel
During the last session, Acer Therapeutics Inc. (NASDAQ:ACER)’s traded shares were 0.48 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $2.41, reflecting an intraday gain of 0.84% or $0.02. The 52-week high for the ACER share is $4.56, that puts it down … After A -20.98% Drop In The Last Week, Does Acer Therapeutics Inc. (NASDAQ: ACER) Still Make Sense To Buy? Read More »
ZyVersa, Jasper top healthcare gainers; Biora, Acer among losers 2023/01/13 15:00:33 Seeking Alpha
ZyVersa Therapeutics (ZVSA) +47%. Jasper Therapeutics JSPR +41%. Biora Therapeutics (BIOR) -15%. Acer Therapeutics (ACER) -10%.
Acer Therapeutics rises on starting trial of ACER-801 in men with adenocarcinoma of the prostate 2023/01/05 14:34:54 Seeking Alpha
Acer Therapeutics (ACER) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of…
How Is The Market Feeling About Acer Therapeutics? 2023/01/03 18:09:28 Benzinga
Acer Therapeutics''s (NASDAQ: ACER ) short percent of float has risen 716.36% since its last report. The company recently reported that it has 657 thousand shares sold short , which is 4.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Have you been able to find a good deal on Acer Therapeutics Inc.’s shares? 2022/08/24 15:08:00 US Post News
Acer Therapeutics Inc. (NASDAQ:ACER) marked $1.51 per share on Tuesday, up from a previous closing price of $1.44. While Acer Therapeutics Inc. has overperformed by 4.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACER fell by -38.37%, with highs and lows ranging from $3.77 to […]
Acer Therapeutics GAAP EPS of -$0.17 beats by $0.42 2022/08/15 21:26:15 Seeking Alpha
Acer Therapeutics press release (ACER): Q2 GAAP EPS of -$0.17 beats by $0.42.Cash and cash equivalents were $14.5 million
Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update 2022/08/15 20:00:00 GlobeNewswire
NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
Acer Therapeutics Inc. (NASDAQ:ACER) Shares Are Up 21.09% From The Lows, But Can They Stay Up? 2022/08/13 12:00:00 Marketing Sentinel
In last trading session, Acer Therapeutics Inc. (NASDAQ:ACER) saw 0.32 million shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $1.47 trading at -$0.01 or -0.67% at ring of the bell on the day assigns it a market valuation of $25.93M. That closing price of ACER’s stock is … Acer Therapeutics Inc. (NASDAQ:ACER) Shares Are Up 21.09% From The Lows, But Can They Stay Up? Read More »
Acer, Relief''s metabolic disorder therapy ACER-001 gets orphan drug status in EU 2022/08/12 13:12:27 Seeking Alpha
The European Commission granted orphan medicinal product designation to Acer Therapeutics (ACER) and Relief Therapeutics'' (RLFTF) (RLFTY) ACER-001 (sodium phenylbutyrate) to treat…
Comparing Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) 2021/12/12 06:12:42 Dakota Financial News
Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and []
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms 2021/12/09 13:30:00 Intrado Digital Media
Phase 2a trial initiation expected in Q1 2022
Acer Therapeutics (NASDAQ:ACER) Stock Rating Upgraded by Zacks Investment Research 2021/12/09 08:36:41 Transcript Daily
Acer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of []
-$0.24 Earnings Per Share Expected for Acer Therapeutics Inc. (NASDAQ:ACER) This Quarter 2021/12/05 14:46:42 Dakota Financial News
Equities analysts expect that Acer Therapeutics Inc. (NASDAQ:ACER) will announce earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Acer Therapeutics earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Acer Therapeutics posted earnings of ($0.50) per share during the same []